AbbVie (NEOE:ABBV) Change In Receivables : C$215 Mil (TTM As of Sep. 2024)

View and export this data going back to 2022. Start your Free Trial

What is AbbVie Change In Receivables?

AbbVie's change in receivables for the quarter that ended in Sep. 2024 was C$466 Mil. It means AbbVie's Accounts Receivable declined by C$466 Mil from Jun. 2024 to Sep. 2024 .

AbbVie's change in receivables for the fiscal year that ended in Dec. 2023 was C$89 Mil. It means AbbVie's Accounts Receivable declined by C$89 Mil from Dec. 2022 to Dec. 2023 .

AbbVie's Accounts Receivable for the quarter that ended in Sep. 2024 was C$15,540 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. AbbVie's Days Sales Outstanding for the three months ended in Sep. 2024 was 72.39.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. AbbVie's liquidation value for the three months ended in Sep. 2024 was C$-161,518 Mil.

AbbVie Change In Receivables Historical Data

The historical data trend for AbbVie's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AbbVie Change In Receivables Chart

AbbVie Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

-97.45

-1,189.96

-1,690.88

-1,976.62

88.55

AbbVie Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Change In Receivables	Get a 7-Day Free Trial															2.71	454.80	-950.23	243.95	465.98

AbbVie Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$215 Mil.

AbbVie (NEOE:ABBV) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

AbbVie's Days Sales Outstanding for the quarter that ended in Sep. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	15539.971	/	19587.516	*	91
=	72.39

2. In Ben Graham's calculation of liquidation value, AbbVie's accounts receivable are only considered to be worth 75% of book value:

AbbVie's liquidation value for the quarter that ended in Sep. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	9868.261	-	186055.665	+	0.75 * 15539.971	+	0.5 * 6027.97
=	-161,518

AbbVie Change In Receivables Related Terms

Thank you for viewing the detailed overview of AbbVie's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

AbbVie Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AbbVie Inc (NEOE:ABBV) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

ABBV:USA ABBV:Mexico 1ABBV:Italy 4ABd:UK 0QCV:UK 4AB:Germany ABBV34:Brazil 4AB:Bulgaria ABBV:Austria ABBV:Argentina

Address

1 North Waukegan Road, North Chicago, IL, USA, 60064-6400

Website

http://www.abbvieinvestor.com

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).